Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated

Federico Pappalardo; G. Maj; A. Scandroglio; F. Sampietro; A. Zangrillo; A. Koster

doi:10.1177/0267659109106773

Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated

Federico Pappalardo, G. Maj, A. Scandroglio, F. Sampietro, A. Zangrillo, A. Koster

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Heparin-induced thrombocytopenia (HIT) is a serious, antibody-mediated complication of heparin which significantly confers risks of thrombosis and devastating outcomes. Once diagnosed, it requires immediate cessation of heparin and therapy with an alternative anticoagulant. No data are available in the literature on the pathophysiology and clinical implications of performing prolonged extracorporeal membrane oxygenation with a heparin-coated system in a patient with acute HIT treated with bivalirudin.

Original language	English
Pages (from-to)	135-137
Number of pages	3
Journal	Perfusion
Volume	24
Issue number	2
DOIs	https://doi.org/10.1177/0267659109106773
Publication status	Published - 2009

Keywords

Bivalirudin
ECMO
Heparin-induced thrombocytopenia
Outcome
Thrombosis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Radiology Nuclear Medicine and imaging
Advanced and Specialised Nursing
Safety Research

Access to Document

10.1177/0267659109106773

Fingerprint Dive into the research topics of 'Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated'. Together they form a unique fingerprint.

Cite this

Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia : The immune reaction appeared to continue unabated. / Pappalardo, Federico; Maj, G.; Scandroglio, A.; Sampietro, F.; Zangrillo, A.; Koster, A.

In: Perfusion, Vol. 24, No. 2, 2009, p. 135-137.

Research output: Contribution to journal › Article › peer-review

@article{c6a974f7077a4326aefa4bd00daf3d32,

title = "Bioline{\textregistered} heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated",

abstract = "Heparin-induced thrombocytopenia (HIT) is a serious, antibody-mediated complication of heparin which significantly confers risks of thrombosis and devastating outcomes. Once diagnosed, it requires immediate cessation of heparin and therapy with an alternative anticoagulant. No data are available in the literature on the pathophysiology and clinical implications of performing prolonged extracorporeal membrane oxygenation with a heparin-coated system in a patient with acute HIT treated with bivalirudin.",

keywords = "Bivalirudin, ECMO, Heparin-induced thrombocytopenia, Outcome, Thrombosis",

author = "Federico Pappalardo and G. Maj and A. Scandroglio and F. Sampietro and A. Zangrillo and A. Koster",

year = "2009",

doi = "10.1177/0267659109106773",

language = "English",

volume = "24",

pages = "135--137",

journal = "Perfusion",

issn = "0267-6591",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia

T2 - The immune reaction appeared to continue unabated

AU - Pappalardo, Federico

AU - Maj, G.

AU - Scandroglio, A.

AU - Sampietro, F.

AU - Zangrillo, A.

AU - Koster, A.

PY - 2009

Y1 - 2009

N2 - Heparin-induced thrombocytopenia (HIT) is a serious, antibody-mediated complication of heparin which significantly confers risks of thrombosis and devastating outcomes. Once diagnosed, it requires immediate cessation of heparin and therapy with an alternative anticoagulant. No data are available in the literature on the pathophysiology and clinical implications of performing prolonged extracorporeal membrane oxygenation with a heparin-coated system in a patient with acute HIT treated with bivalirudin.

AB - Heparin-induced thrombocytopenia (HIT) is a serious, antibody-mediated complication of heparin which significantly confers risks of thrombosis and devastating outcomes. Once diagnosed, it requires immediate cessation of heparin and therapy with an alternative anticoagulant. No data are available in the literature on the pathophysiology and clinical implications of performing prolonged extracorporeal membrane oxygenation with a heparin-coated system in a patient with acute HIT treated with bivalirudin.

KW - Bivalirudin

KW - ECMO

KW - Heparin-induced thrombocytopenia

KW - Outcome

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=68449083833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449083833&partnerID=8YFLogxK

U2 - 10.1177/0267659109106773

DO - 10.1177/0267659109106773

M3 - Article

C2 - 19654158

AN - SCOPUS:68449083833

VL - 24

SP - 135

EP - 137

JO - Perfusion

JF - Perfusion

SN - 0267-6591

IS - 2

ER -

Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: The immune reaction appeared to continue unabated

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this